Regeneron Pharmaceuticals【REGN34】銘柄情報 | ADVFN

US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
ブラジル
BOV
Regeneron Pharmaceuticals Inc (REGN34) 銘柄情報

Regeneron Pharmaceuticals Inc (REGN34)

72.45

0.35

(0.49%)

終了 11月27日 5:55AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

72.45

買値

70.00

売値

105.00

出来高

150

72.45 日の範囲 73.15

64.40 52 週間の範囲 111.72

時価総額

前日終値

72.10

始値

73.15

時刻

最終取引時間

財務取引量

R$ 10,889

VWAP

72.59

平均取引量 (3 か月)

776

発行済株式数

107,129,000

配当利回り

-

PER

20.40

1 株当たり利益 (EPS)

36.91

歳入

13.12B

純利益

3.95B

セクター

Pharmaceutical Preparations

業界

Health Care Diversified

ウェブサイト

www.regeneron.com

本社

New York, New York, USA

設立

1988

Regeneron Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ボベスパ (ブラジル) with ticker REGN34. The last closing price for Regeneron Pharmaceuticals was R$72.10. Over the last year, Regeneron Pharmaceuticals shares have traded in a share price range of R$ 64.40 to R$ 111.72.

Regeneron Pharmaceuticals currently has 107,129,000 shares in issue. The market capitalisation of Regeneron Pharmaceuticals is R$7.72 billion. Regeneron Pharmaceuticals has a price to earnings ratio (PE ratio) of 20.40.

No news to show yet.

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.07	-0.0965250965251	72.52	73.15	71.26	5375	72.08175989	DR
4	-17.1	-19.0954773869	89.55	89.55	71.26	1416	73.25371557	DR
12	-39.09	-35.0457235073	111.54	111.54	71.26	776	84.98444595	DR
26	-12.62	-14.8348418949	85.07	111.72	71.26	790	92.01193627	DR
52	7.28	11.1707841031	65.17	111.72	64.4	643	88.08450301	DR
156	11.11370959	18.1193050895	61.33629041	111.72	46.67549008	765	72.3902656	DR
260	46.98435641	184.5009581	25.46564359	111.72	24.99666458	531	67.20972721	DR

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MWET4Wetzel Sa (ex Metalurgica Wetzel Sa)	R$ 17.01 (30.85%)	11k
PPLA11PPLA Participations Ltd	R$ 2.25 (15.38%)	823
BHIA3Grupo Casas Bahia SA	R$ 4.09 (11.14%)	6.53M
BRAV3Brava Energia	R$ 20.86 (9.33%)	19.3M
VIVR3Viver Incorporadora e Construtora SA	R$ 1.43 (9.16%)	277k
RPAD3Alfa Holdings Sa (ex Real Sa Participacoes Administracao)	R$ 6.75 (-14.99%)	1.2k
ATOM3Atom Empreendimentos e Participacoes SA	R$ 4.19 (-10.47%)	342.7k
OSXB3OSX Brasil SA	R$ 3.96 (-8.97%)	27.3k
IFCM3Infracommerce Caxaas S.A.	R$ 0.11 (-8.33%)	1.87M
TRAD3TC S.A.	R$ 6.80 (-6.85%)	143.1k
COGN3CognaEducacao SA	R$ 1.47 (2.08%)	57.05M
HAPV3Hapvida Participacoes Investimento SA	R$ 3.05 (0.99%)	50.75M
CVCB3CVC Brasil Operadora E Agencia De Viagens SA	R$ 2.84 (3.27%)	44.95M
MGLU3Magaz Luiza	R$ 10.64 (6.29%)	36.38M
OIBR3Oi	R$ 1.69 (7.64%)	35.24M

SkeBallLarry

SkeBallLarry 1分前

" Grreat choice indeed, Bull ~ Good morning " .. !!

Bull_Dolphin

Bull_Dolphin 1分前

Just another lying biotch:

https://www.msn.com/en-us/politics/government/alexandria-ocasio-cortez-says-she-doesn-t-take-lobbyist-cash-records-tell-a-different-story/ar-AA1uO0iy

STILL TOWING

STILL TOWING 3分前

Get ready, The dream team will probably say, Ward woulda pulled off the immaculate storage facility, but Trumps tariff policy blew it.. Now we gotta wait till the next administration.. But hopefully by then, the prominent family backing ward will have been vetted..LOL...You heard it here first. :)

Bull_Dolphin

Bull_Dolphin 4分前

Great Choice:

https://redstate.com/bobhoge/2024/11/26/trump-nominates-stanford-professor-who-sounded-alarm-on-covid-lockdownsand-was-censoredfor-dir-of-nih-n2182519

Seminole Red

Seminole Red 6分前

All Russian migrants being denied access to asylum process, says attorney

https://www.msn.com/en-us/news/politics/all-russian-migrants-being-denied-access-to-asylum-process-says-attorney/ar-AA1uMXhl?ocid=msedgntphdr&cvid=428e06a617894bb1e40a5b4dedbbe2f1&ei=309

A

Just the facts maam

Just the facts maam 7分前

That sounds extraordinary to me. It would explain why they never disclosed any info Tezruly and the other two drugs.

sab63090

sab63090 8分前

Tom:
I like your plan and being flexible, too....that's always the best way to look at things, especially after news and potential additional news, we need to adapt, wait, observe and then take our chances...in and out trading forces you to be correct more than your losses & some people can't

jeunke22

jeunke22 8分前

https://www.laserfocusworld.com/optics/article/55140912/electro-optic-polymers-are-a-potential-enabler-of-quantum-computing

WhirlwindCosmonaut85

WhirlwindCosmonaut85 11分前

https://lacdmhowr.powerappsportals.us/forums/support-forum/48a1e2c0-a5ac-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/support-forum/418da8cf-a4ac-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/support-forum/3a312712-a2ac-ef11-b542-001dd8097a1

TrendTrade2016

TrendTrade2016 13分前

maggot you made yet another fool out of yourself...A you can't short otc and B shorting the NASDAQ YOU need 200 GRAND IN YOUR MARGIN ACCOUNT AND THE ONLY STOCK YOU OWN IS THE SCAM AHRO...YOU LOST MOST OF YOUR MONEY IN THE MARKET AND YOU ARE A LYING POS...I CALLED THIS AT 1.90 IN PRE MARKET CLOWN B

Kenneth Howell

Kenneth Howell 16分前

Don’t be surprised if it sees 120 to 110 in the next 2 weeks. It does this after every earnings. Sell the news event. It usually bottoms 1 to 2 months after earnings then starts it rise to new highs . I have the December 20 ,110 puts. Will buy calls most likely in January.GLTA!

Bruno2

Bruno2 16分前

The table below shows currently available funds.

https://californiahvip.org/funding/

CaptainObvious

CaptainObvious 23分前

We're only allowed one sticky each. I have the Jama article.

Perhaps you or someone could compile a post containing all worthy to be stickied posts, with headings for each, and I can replace my current one.

Horseb4CarT

Horseb4CarT 24分前

Looks pretty useful however it keeps the details for those who pay for the research.

Any of you rich cats paid for the report and can share the details?

It seems like a big positive for dcvaxL and nwbo to be in the report, with dcvaxL listed first in the cancer vaccine

IXCHIQ: Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

https://valneva.com/press-release/valneva-submits-label-extension-application-for-its-chikungunya-vaccine-ixchiq-to-the-u-s-fda/

Saint Herblain (France), November 2

i_dont_know

i_dont_know 25分前

The reduction of liabilities is always a positive step since it eases the burden of interest expenses on the company’s results, especially when it comes to toxic financing like the Hypur convertibles. However, what good is reducing debt if there’s no clear business case in sight? Current and prospec

weedtrader420

weedtrader420 25分前

Edward

Edward 27分前

What???

No kidding!!!! That is just explaining that someone can sell a stock while it is in the Expert markrt!!

GEEZ!!!! OMG!

weedtrader420

weedtrader420 27分前

☝️🐶☝️✖️

ShawnP123

ShawnP123 33分前

It is sinking fast in the pre-market. This could be another $3-$6 red day. Jensen has a problem in regards to his Q conference. He needs professional help with what he should and how to report it. Instead his CFO Q&A was like using gasoline to put out a fire.

Budman33

Budman33 34分前

Maybe we close .0120 plus we were up over 40% @ one point late afternoon. Now when I dream I drop that first 0,,,, .12. Then wake up.

Truth and Transparency

Truth and Transparency 36分前

At the end of the day, Mark has come up short for the past 10 years. Payday loans to keep the lights on and a devastating share price as a result is what we have now.

NinjaFortress80

NinjaFortress80 38分前

https://lacdmhowr.powerappsportals.us/forums/support-forum/751aecbd-8fac-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/support-forum/79ad0f39-9bac-ef11-b542-001dd8097a1a
https://lacdmhowr.powerappsportals.us/forums/support-forum/9a793ccf-98ac-ef11-b542-001dd8097a1

Regeneron Pharmaceuticals

BNP Paribas Issuance

Peyto Exploration and De... (PK)

Protocol Finance

Ivz Us Trea 10+

Broadway Gold Mining

BNP Paribas Issuance

BNP Paribas Issuance

Bnp Paribas Issuance

BNP Paribas Issuance

BNP Paribas Issuance

Global Payments

Low Carbon 100 Europe Ne...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約